Author:
Henkenberens Christoph,Wildfang Ingeborg
Publisher
Springer Berlin Heidelberg
Reference77 articles.
1. Abitol AA, Sridhar KS, Lewin AA, Schwade JG, Raub W Jr, Wolfson A, Gonzalez-Angulo C, Adessa A, Goodwin WJ, Markoe AM (1997) Hyperfractionated radiation therapy and 5-fluororacil, ciplatin, and mitomycin- (+/- granulocyte-colony stimulating factor) in the treatment of patients with locally advanced head and necl carcinoma. Cancer 80:266–276
2. Ak N, Mauch PM (2009) Late effects of Hodgkin’s disease and its treatment. Cancer J 15:164–168
3. Antanadou D, Cardamakis E, Sarris G, Tzigounis V (1998) Effect of administration of recombinant human erythropoietin in patients with pelvic malignancies during radiotherapy. Radiother Oncol 48(Suppl 1): Abstract 483
4. Blohmer JU, Paepke S, Sehouli J, Boehmer D, Kolben M, Würschmidt F, Petry KU, Kimmig R, Elling D, Thomssen C, von Minckwitz G, Möbus V, Hinke A, Kümmeöl S, Budach V, Lichtenegger W, Schmid P (2011) Randomized phase II trial of sequential adjuvant chemoradiotherapy with or without erythropoietin Alfa in patients with high-risk cervical cancer: results of the NOGGO-AGO intergroup study. J Clin Oncol 29:3791–3997
5. Bohlius J, Langensiepen S, Schwarzer G, Seidenfeld J, Piper M, Bennet C, Engert A (2005) Recombinant human erythropeotin and overall survival in cancer patients: results of a comprehensive meta-analysis. J Natl Cancer Inst 97:489–498